Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4491-4497

  Olmos, José M ^a   Herńandez, José L ^a   Llorca, Javier ^a   Nan, Daniel ^a   Valero, Carmen ^a   González Maćias, Jesuś ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIFEDIOL; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE;

AGED; AMINO TERMINAL PROPEPTIDE OF TYPE I COLLAGEN BLOOD LEVEL; ARTICLE; BONE TURNOVER; C TERMINAL TELOPEPTIDE OF TYPE I COLLAGEN BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORNING DOSAGE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFEDIOL; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; TREATMENT OUTCOME;

EID: 84870762774     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2999     Document Type: Article

References (22)

1. Boonen S, Vanderschueren D, Haentjens P, Lips P 2006 Calcium and vitamin D in the prevention and treatment of osteoporosis: a clinical update. J Intern Med 259:539-552
2. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
3. Dawson-Hughes BD, Lindsay R, Khosla S, Melton LJ III, Favus M, Baim S 2008 Clinicians's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; www.nof.org/professionals/clinical- guidelines
4. 3 and weekly alendronate 70 mg in men and women with osteoporosis. Ann Pharmacother 45:561-568
5. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group 2006 Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study. J Bone Miner Res 21:1565-1570
6. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, Agnusdei D, Gentilella R, Nuti R; ICARO Study Group 2008 Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 19:1219-1223
7. Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Muñoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, González-Macías J 2012 Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817-824
8. Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE 2009 Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int 20:1259-1266
9. Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H 2009 Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398-404
10. Carmel AS, Sieh A, Bang H, Bockman RS 2012 The 25(OH)D level needed to maintain a favorable BP response is ≥33 ng/ml. Osteoporos Int 10.1007/s00198-011-1868-7
11. Chung HY, Chin SO, Kang MI, Moon SH, Yoon BK, Yoon HK, Chung YS, Park HH 2011 Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clin Endocrinol (Oxf) 74:699-740
12. Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P 2009 Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: Global perspective. J Bone Miner Res 24:693-701
13. 3: effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone Miner Res 27:160-169
14. Russo S, Carlucci L, Cipriani C, Ragno A, Piemonte S, Fiacco RD, Pepe J, Fassino V, Arima S, Romagnoli E, Minisola S 2011 Metabolic changes following 500μg monthly administration of calcidiol: a study in normal females. Calcif Tissue Int 89:252-257
15. Berry EM, Gupta MM, Turner SJ, Burns RR 1973 Variations in plasma calcium with induced changes in plasma specific gravity, total protein, and albumin. Br Med J 4:640-643
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461-470 (Pubitemid 29135798)
17. Looker AC, Orwoll ES, Johnston Jr CC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP 1997 Prevalence of low femoral bone density in old U.S. adults from NHANES III. J Bone Miner Res 12:1761-1768 (Pubitemid 27500187)
18. Riancho JA, Valero C, Hernandez JL, Olmos JM, Paule B, Zarrabeitia A, Gonzalez-Macias J 2007 Biomechanical indices of the femoral neck estimated from the Standard DXA output: age- and sex-related differences. J Clin Densitom 10:39-45 (Pubitemid 46199282)
19. Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Muxi A, Guañabens N 2012 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54-58
20. Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B 2012 A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40-49
21. Holvik K, Madar AA, Meyer HE, Lofthus CM, Stene LC 2012 Changes in the vitamin D endocrine system and bone turnover after oral vitamin D3 supplementation in healthy adults: results of a randomised trial. BMC Endocr Disord 12:7
22. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G 2007 Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density in response to alendronate in elderly women with osteoporosis: A randomized controlled trial. J Am Geriatr Soc 55:752-757 (Pubitemid 46668979)